BALB/c mice immunized with Pseudomonas aeruginosa immunotype 1 polysaccharide develop protective T cell immunity to bacterial challenge. In vitro, T cells from immunized mice kill P. aeruginosa by production of a bactericidal lymphokine. The present study demonstrates that adoptive transfer of T cells from immunized BALB/c mice to granulocytopenic mice resulted in 97% survival on challenge with P. aeruginosa, compared with 17% survival with adoptive transfer of T cells from nonimmune BALB/c mice. This protection is specifically elicited by reexposure to the original immunizing antigen; adoptive recipients cannot withstand challenge with immunotype 3 P. aeruginosa. However, the adoptive recipients do survive simultaneous infection with both P. aeruginosa immunotypes 1 and 3. Adoptive transfer of T cells from the congenic CB.20 mice, which are unable to kill P. aeruginosa in vitro, provides only 20% protection to granulocytopenic mice. These studies indicate that transfer of specific immune T lymphocytes can significantly enhance the resistance to P. aeruginosa infection in granulocytopenic mice.
Introduction
Analysis of immune resistance to infection with gram-negative extracellular bacteria has focused on the role of antibody, complement, and phagocytic cells in destroying these organisms (1) . The predisposition of granulocytopenic patients to develop infection with gram-negative bacteria has been cited as evidence for the importance of these cells in resistance to such infections (2) . Pseudomonas aeruginosa (P. aeruginosa)' is an important bacterial pathogen in granulocytopenic hosts and, despite advances in antimicrobial therapy, this organism remains an important cause of morbidity and mortality in such patients (3) . Attempts to modulate the course of P. aeruginosa infection in leukopenic patients using granulocyte transfusions and serotherapy have had only limited success (4, 5) .
The role of T lymphocytes in resistance to infection with gram-negative bacteria has been thought to be limited to regulation of the antibody response. We have previously demonstrated that T lymphocytes from BALB/c mice given the cytotoxic agent vinblastine sulfate and a polysaccharide (PS) antigen isolated from P. aeruginosa immunotype 1 (IT-1) can adoptively transfer resistance to infection to nonimmune mice (6) . We also established that splenic T cells obtained from immunized mice could kill P. aeruginosa in vitro (7) . After in vitro reexposure to the immunizing antigen, T cells from immune mice secrete a lymphokine that kills a broad range ofgram-negative and grampositive bacteria (7) . This killing requires the presence of neither antibody nor complement, and it occurs in the absence of phagocytic cells (7) .
The murine T cell that mediates the bactericidal effect is of the Lyt 1-, 2+ phenotype and reacts with monoclonal antibodies directed at the putative I-Jd antigen (8) . Macrophages are required in this system only as a source of interleukin 1 (IL-1) (8) , and function neither as antigen-presenting cells nor as phagocytic cells. In addition, we have identified a strain of mouse, CB.20, congenic with BALB/c mice at the Igh-1 locus, that fails to kill P. aeruginosa in this in vitro model (9) . The nonresponsiveness of this strain is attributable to the activity of suppressor T cells (9) .
The current studies were designed to investigate further the in vivo significance of this T lymphocyte-mediated immune response. Using a murine model ofgranulocytopenia, we found that adoptive transfer of immune T cells could protect mice from a lethal challenge with P. aeruginosa, even in the absence ofgranulocytes; but protection could not be achieved with nonimmune T cells, nor with immune B cells. T cells from the CB.20 mice, which did not kill P. aeruginosa in our in vitro assay, are also incapable ofadoptively transferring protection in vivo, establishing that the ability to confer protection correlates with the in vitro bactericidal activity ofimmune T cells. P. aeruginosa IT-1 immune T cells are unable to protect granulocytopenic mice infected with P. aeruginosa immunotype 3 (IT-3). Adoptive transfer ofIT-1 immune T cells is, however, protective against simultaneous challenge with both P. aeruginosa IT-1 and IT-3, indicating that in vivo reexposure to the homologous immunizing antigen elicits a nonspecific protective response.
Methods
Bacteria. The Fisher-Devlin IT-I and IT-3 strains ofP. aeruginosa (originally provided by Dr Serologic assay. Murine sera was obtained via retroorbital bleeding of halothane-anesthetized mice. Concentrations of antibody were determined using a radioimmunoassay as described (12) . The antigen used was intrinsically labeled '4C-PS prepared as described (12) . The 
Results
Protection ofgranulocytopenic mice by adoptive transfer of immune T cells. T lymphocytes from immunized and unimmunized BALB/c mice were adoptively transferred to granulocytopenic BALB/c mice 18 h before challenge with P. aeruginosa, and mouse survival was determined (Table I ). In exp. 1, 5 X 107
immune T cells protected 100% of granulocytopenic mice from intraperitoneal challenge with 100 CFU ofP. aeruginosa, whereas only 33% of mice given nonimmune T cells survived. In the second experiment, granulocytopenic mice were given a lower number of T lymphocytes (3 X 107) and a larger challenge inoculum (260 CFU). 67% of the mice given immune T cells survived, compared with no survival in mice given nonimmune T cells. Furthermore, the mean survival time between the two groups, 144±19. Previous work has demonstrated that the development of a protective immune response in vivo (6) and the development of a bactericidal T cell response in vitro (7) requires immunization with both PS and vinblastine. Although the mechanism of action of vinblastine in this system is not fully defined, preliminary evidence indicates that vinblastine eliminates a suppressor cell that inhibits the killing capability of the bactericidal T cells (1 5a). To confirm that the adoptively transferred in vivo protection correlates with our in vitro observations, we compared survival in granulocytopenic mice given T cells from mice immunized with both PS and vinblastine to survival in granulocytopenic mice given T cells from donor mice immunized with either PS or vinblastine alone. T lymphocytes from mice immunized with both PS and vinblastine protected 100% of mice challenged with P. aeruginosa, whereas there was no survival in mice given cells from either mice immunized with vinblastine (Table II, (9) . We therefore compared the ability of immune T cells from CB.20 mice to protect granulocytopenic BALB/c mice with the protective ability of immune T cells transferred from BALB/c mice. The results of two such experiments are shown in Table IV . Both experiments show that immune cells from BALB/c mice protected 100% of challenged granulocytopenic mice compared with 20% protection with cells from immunized CB.20 mice. CB.20 and BALB/c mice are identical at the major histocompatibility (H-2) locus, but it is uncertain whether these two strains are identical at other minor histocompatibility sites. That the inability of CB.20 T cells to protect granulocytopenic BALB/c mice is not due to minor histoincompatibilities is shown by the ability of T cells from immunized BALB/c mice to protect 100% of infected granulocytopenic CB.20 mice (Table V) .
Specificity of T cell-mediated protection. Previous studies have shown that the in vitro bactericidal activity of T lymphocytes obtained from mice immunized with IT-1 PS is specific for the immunizing immunotype (7). We examined the effectiveness of adoptively transferred T cells obtained from mice immunized with IT-I PS in infection with P. aeruginosa IT-3 to determine the in vivo specificity of the protection. IT-I immune T cells, which protect 100% of granulocytopenic mice infected with P. aeruginosa IT-1 (Table VI, fected with P. aeruginosa IT-I and IT-3. In vitro studies have demonstrated that the T cell-mediated bactericidal effect can be attributed to the activity ofa bactericidal lymphokine, which, once elicited by specific antigenic challenge of immune T cells, is nonspecifically effective against a broad range of both gramnegative and gram-positive bacteria (7) . The previous experiment confirmed in vivo that challenge with an'unrelated antigen does not activate protective T cell immunity. In this experiment we evaluated whether activating protective T cell immunity by challenge with' the homologous antigen (P. aeryginosa IT-i) could protect against simultaneous infection with an unrelated antigen (P. aeruginosa IT-3). The results of a representative experiment (Table VII) indicate that such cross-protection can, in fact, be elicited. 86% of granulocytopenic mice that received IT-I immune T cells survived simultaneous challenge with IT-1 and IT-3 P. aeruginosa. Granulocytopenic mice receiving nonimmune T cells did not survive challenge with the two immunotypes, and no survival was seen in granulocytopenic mice that received IT-I immune T cells and were challenged with IT-3 P. aeruginosa. These observations suggest that in vivo the final mediator of protection is nonspecific in its effect, but this nonspecific protection can only be elicited by exposure to the original immunizing antigen, the PS from IT-I P. aeruginosa. 
Discussion
We have previously observed that BALB/c mice fail to produce specific antibody when immunized with low doses of a purified PS obtained from P. aeruginosa. Nevertheless, these mice are capable of generating protective immunity that is mediated by T lymphocytes (6) .'T lymphocytes from immune mice can transfer protection to nonimmune, immunologically intact mice that are given an otherwise lethal challenge of 1 O P. aeruginosa (6) . In vitro Lyt 1, 2+, I-J+ T cells from BALB/c mice immunized with PS and vinblastine kill P. aeruginosa by secretion of a bactericidal lymphokine (7, 8) . This killing mechanism is remarkably independent of the function of other cells, including macrophages, except that the presence of IL-1, provided by macrophages, results in significant enhancement of the observed T cell-mediated killing (8) . T cells from immunized CB.20 mice, which are congenic with BALB/c mice at the Igh-I locus, fail to kill P. aeruginosa in vitro (9) . This failure is attributable to the activity of a population of suppressor T cells generated in CB.20 mice by PS immunization (9) . (17, 18) . Our studies and those of others (19, 20) clearly indicate that PSactivated T cells may function not merely as regulatory cells but also as effector cells in resistance to bacterial infection.
Control ofviral infection by immune T cells has been shown to be directed only at the eliciting antigen and to require direct cell-to-cell contact. Clones of cytolytic T cells directed against specific influenza virus strains are unable to protect mice simultaneously infected with two strains of influenza virus (21) . However, our studies indicate that such specificity is not required in vivo with the T cell response elicited by P. aeruginosa PS, provided there is reexposure to the immunizing antigen. This observation correlates with the in vitro finding that secretion of a bactericidal lymphokine with broad antibacterial activity occurs when immune T lymphocytes are reexposed to the immunizing antigen (7) . These studies therefore support the hypothesis that in vivo protection is mediated by secretion of a nonspecifically effective bactericidal lymphokine.
In addition to demonstrating the protective efficacy of immune T cells in the granulocytopenic mouse, these investigations also provide some preliminary indication of how immune T cells might function in the intact host to prevent infection. It is clear that circulating immune T cells are capable of controlling localized infections (intraperitoneal in the current studies) with extracellular bacteria in the absence of circulating granulocytes or antibody. While circulating antibody is undoubtedly more efficient at promoting opsonization of overwhelming numbers ofbacteria, most infections, including those in leukopenic hosts, begin with the appearance of small numbers of bacteria at an otherwise sterile site within the host (22) .
Using our PS immunization protocol, T cell immunity to P. aeruginosa is generated more readily than antibody-mediated immunity (23) , and this finding is consistent with other studies showing that T cells are activated by smaller amounts ofantigen than are B cells (24, 25) . It is, therefore, likely that many individuals exposed to Pseudomonas antigens may develop T cell immunity without possessing protective levels of antibody. In vitro studies in our laboratory indicate that anti-Pseudomonas bactericidal capability ofhuman T cells is, in fact, more prevalent than protective levels of antibody (1 1) (Markham, R. B., unpublished observations).
Immunization of mice with PS alone does not elicit a bactericidal response in vitro (7) or a protective response in vivo (6) . Vinblastine is required for an optimal response and functions by the inhibition of a population of suppressor cells generated in response to PS immunization (1 5a). However, ongoing work in our laboratory has demonstrated that exposure to as few as 102 live P. aeruginosa can generate splenic T lymphocytes that are bactericidal in vitro and capable of adoptively transferring resistance to lethal infection in vivo (Markham R. B., J. J. Goellner, G. B. Pier and W. G. Powderly, manuscript submitted for publication). It therefore becomes reasonable to hypothesize that T cell immunity to extracellular bacteria may, with these bacteria, be a more primitive first line of defense against infection and may play a critical role in the prevention ofestablished infections that could result from the frequent low level ofbacterial invasion encountered by the normal host.
Attemps to reconstitute resistance to infection in leukopenic hosts with transfusion of granulocytes has had only limited success (26) , perhaps due in part to the requirement for more complex immune responses, such as antibody production, for optimal neutrophil function (27) . Our studies demonstrate that immune T cells can protect granulocytopenic mice from lethal P. aeruginosa infection without the additional requirement ofantibody or phagocytic cells. Since, as in our model, infection in the immunosuppressed human host begins with localized infections (22) , it would now seem appropriate to study the ability of enhancing T cell immunity to reduce the incidence of infectious complications in the immunosuppressed patient.
